Maintenance therapy with lenalidomide, dexamethasone and clarithromycin (Biaxin) following autologous/syngeneic transplant for multiple myeloma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Lenalidomide (Primary) ; Clarithromycin; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 04 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2018 according to the ClinicalTrials.gov record.
- 23 Jan 2014 Planned End Date changed from 1 Jan 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.
- 05 Feb 2013 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.